Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
25.56
Nov 20 • 3:06 PM ET Dollar change-0.95 Percentage change(-3.58%)
Index
RUT
Market Cap
1.03B
Enterprise Value
723.90M
Income
-95.18M
Sales
0.00M
Book/sh
7.42
Cash/sh
7.96
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
68
IPO
Feb 02, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.45
P/C
3.21
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
18.12
Current Ratio
18.12
Debt/Eq
0.06
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-2.49
EPS next Y
-2.70
EPS next Q
-0.62
EPS this Y
-15.28%
EPS next Y
-6.77%
EPS next 5Y
-9.01%
EPS past 3/5Y
-26.47% -57.17%
Sales past 3/5Y
- -
EPS Y/Y TTM
-8.20%
Sales Y/Y TTM
-
EPS Q/Q
-3.19%
Sales Q/Q
-
Insider Own
9.40%
Insider Trans
-5.27%
Inst Own
96.28%
Inst Trans
6.27%
ROA
-40.20%
ROE
-46.65%
ROIC
-30.84%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
0.70%
SMA50
-0.09%
SMA200
2.23%
Trades
Shs Outstand
39.98M
Shs Float
36.34M
52W High
37.48 -31.80%
52W Low
12.51 104.32%
Volatility
8.78% 8.02%
ATR (14)
2.08
RSI (14)
49.11
Beta
1.15
Rel Volume
0.41
Avg Volume
606.80K
Volume
215,094
Perf Week
-13.47%
Perf Month
15.14%
Perf Quarter
-29.49%
Perf Half Y
20.45%
Perf YTD
43.60%
Perf Year
80.64%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
26.51
Price
25.56
Change %
-3.58%
Consensus
Strong Buy
Avg. Price Target
$38.88
Implied Upside
+52.1%
Analysts11incl. previous ratings
Rating Distribution9 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 22, 2026Initiated
WWolfe Research
Outperform
May 05, 2026Initiated
BAC logoBBofA Securities
Buy$35+36.9%
Jan 05, 2026Resumed
CChardan Capital Markets
Buy$30+17.4%
Nov 17, 2025Initiated
BBTIG Research
Buy
Sep 29, 2025Initiated
CChardan Capital Markets
Buy$15-41.3%
Oct 23, 2024Downgrade
WWedbush
Outperform → Neutral$29 → $4-84.4%
Oct 23, 2024Downgrade
RRodman & Renshaw
Buy → Neutral
Sep 03, 2024Initiated
WWedbush
Outperform$29+13.5%
Feb 27, 2024Initiated
WWilliam Blair
Outperform
Feb 27, 2024Initiated
TD logoTTD Cowen
Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hanley Jr. Michael ConickCHIEF OPERATING OFFICERNov 16 '26Option Exercise2.3570,000164,50070,000Nov 18 07:32 PM
Hanley Jr. Michael ConickCHIEF OPERATING OFFICERNov 18 '26Option Exercise2.352,8966,8062,896Nov 18 07:32 PM
Hanley Jr. Michael ConickCHIEF OPERATING OFFICERNov 17 '26Option Exercise2.352,1044,9442,104Nov 18 07:32 PM
Hanley Jr. Michael ConickCHIEF OPERATING OFFICERNov 16 '26Sale27.6870,0001,937,2820Nov 18 07:32 PM
Hanley Jr. Michael ConickCHIEF OPERATING OFFICERNov 18 '26Sale26.482,89676,6860Nov 18 07:32 PM
Hanley Jr. Michael ConickCHIEF OPERATING OFFICERNov 17 '26Sale26.822,10456,4210Nov 18 07:32 PM
MICHAEL HANLEYOfficerNov 16 '26Proposed Sale29.5475,0002,215,500Nov 16 04:45 PM
Smith Nicholas ConradPRESIDENT AND CFOOct 02 '26Option Exercise2.3255,000127,60079,060Oct 05 04:59 PM
Smith Nicholas ConradPRESIDENT AND CFOSep 29 '26Option Exercise2.35110,830260,450134,890Oct 01 09:33 PM
Smith Nicholas ConradPRESIDENT AND CFOSep 30 '26Option Exercise2.3524,05656,53248,116Oct 01 09:33 PM
Smith Nicholas ConradPRESIDENT AND CFOSep 29 '26Sale26.58110,8302,946,15024,060Oct 01 09:33 PM
Smith Nicholas ConradPRESIDENT AND CFOSep 30 '26Sale25.8224,056621,09724,060Oct 01 09:33 PM
NICHOLAS SMITHOfficerSep 29 '26Proposed Sale26.66134,8863,596,061Sep 29 04:23 PM
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.
Ph.D.Dr. Amit Etkin M.D.
CFO & PresidentMr. Nicholas C. Smith
Chief Operating OfficerMr. Michael C. Hanley M.B.A.
BComMr. Dan Segal B.Sc. (Hons)
General CounselMs. Erin R. McQuade J.D.